SignatureFD’s Accelerate Diagnostics AXDX Stock Holding History

SignatureFD’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13	Closed	-$1K	–	3108
2021 Q3	$1K	Buy	+13	New	+$848	﹤0.01%	2773

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

SignatureFD's AXDX Position: Q4 2021 in Review

SignatureFD sold out of Accelerate Diagnostics (AXDX) in Q4 2021, closing a stake of 13 shares — an estimated $1K sold.

SignatureFD first reported a position in AXDX in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2021.

SignatureFD reported no remaining Accelerate Diagnostics position as of Q4 2021 after selling out during the quarter.
SignatureFD sold 13 Accelerate Diagnostics shares in Q4 2021, an estimated $1K.
SignatureFD first reported a position in Accelerate Diagnostics in Q3 2021 and held it in 1 quarter.
SignatureFD's Accelerate Diagnostics position peaked at $1K in Q3 2021.
107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2021.

Based on SignatureFD's 13F filing for Q4 2021, filed 25 Jan 2022.